USER:
Given the presence of a KRAS p.G12C mutation, what are the potential benefits and risks of transitioning to KRAS-directed treatment with adagrasib? How might this change the patient's prognosis?

---

ASSISTANT (agent id: Orchestrator):
Planned moderation steps:
- Clarify the user’s goal and confirm the workflow plan and sequence.
- Gather the minimum required patient information to enable agent-specific responses.
- Orchestrate agent participation in a logical order; ensure each agent states needs and returns results.
- Provide micro-updates after each agent response and outline next steps.
- Prevent clinical recommendations from being given directly by me; route such content through the appropriate agent(s).
- Validate that outputs meet each agent’s requirements and are aligned to the user’s question.

Proposed plan and participation order:
1) PatientHistory → retrieve the patient’s timeline and key oncology history using a valid patient ID.
2) PatientStatus → compile a current, structured status (age, primary site, histology, stage, biomarkers, ECOG, prior treatments).
3) ClinicalGuidelines → explain potential benefits and risks of transitioning to KRAS-directed treatment with adagrasib and how this might influence prognosis, based on the patient status.
4) ClinicalTrials → identify relevant trials for KRAS p.G12C given the compiled patient status.
5) MedicalResearch → summarize current evidence and outcomes data related to adagrasib in KRAS p.G12C (e.g., efficacy, safety profiles, subgroups).
6) ReportCreation → optionally generate a tumor board-ready document pulling together the above.
7) Radiology → optional; if you have imaging, Radiology can review. If no imaging is available, Radiology will note that and yield back.

Special rule:
Each agent, after completing their task, must yield the chat back to me (the Orchestrator). Each agent should conclude with: "back to you: Orchestrator".

User, to proceed:
- Please provide the patient ID as a string so PatientHistory can retrieve the record.
- If you do not have a patient ID, we can either:
  - Proceed with a general evidence overview via MedicalResearch while we wait for details, or
  - You can directly provide key details to enable PatientStatus to proceed: age, primary tumor site (e.g., NSCLC vs colorectal), histology, stage, ECOG performance status, full biomarker panel (including KRAS p.G12C and any co-alterations), prior treatments and dates, presence of brain metastases, notable comorbidities, and current medications.
- Optional: If you have recent imaging (CT/MRI/X-ray) and want Radiology input, please share the imaging or confirm that none is available.

Please confirm this plan. Once confirmed, I will begin by calling PatientHistory. If you prefer a general overview first (without patient specifics), I will begin with MedicalResearch instead.

---

USER:
Orchestrator: Plan confirmed. Proceeding with the proposed workflow. Initiating PatientHistory for patient_4 now.

PatientHistory: Attempting retrieval for patient ID "patient_4".
- Data sources searched: oncology EHR summary, prior clinic notes, pathology, molecular profiling, systemic therapy administration logs, radiology impressions, and problem list.
- Result: No structured record for "patient_4" is available in the shared workspace. To proceed, please supply key details so we can construct the status:
  - Primary tumor type and histology (e.g., NSCLC adenocarcinoma vs colorectal adenocarcinoma)
  - Stage and sites of disease; presence/absence of brain metastases
  - ECOG performance status
  - Biomarker panel: KRAS p.G12C confirmed; any co-mutations (e.g., STK11, KEAP1, TP53), PD-L1 (if NSCLC), MSI/MMR/TMB (if CRC/other)
  - Prior lines of therapy with dates and best responses (e.g., platinum/IO, docetaxel, anti-EGFR if CRC, etc.)
  - Comorbidities and current medications (for potential interactions, QTc risk, hepatic function)
  - Recent labs (AST/ALT, bilirubin, creatinine) and QTc if available
back to you: Orchestrator

Orchestrator: Micro-update: PatientHistory could not retrieve a record for patient_4. While we await minimal clinical details from you, I’ll proceed with a general evidence overview to inform potential benefits/risks of transitioning to adagrasib for KRAS p.G12C. After that, we can tailor recommendations once we have the patient specifics. Moving to MedicalResearch.

MedicalResearch: General evidence summary for KRAS p.G12C and adagrasib (MRTX849)

Indications and setting
- Non–small cell lung cancer (NSCLC): Adagrasib is FDA-approved for KRAS p.G12C–mutant NSCLC after at least one prior systemic therapy. Most data are in patients previously treated with platinum-based chemotherapy and immunotherapy.
- Colorectal cancer (CRC): Adagrasib monotherapy has modest activity; combination with anti-EGFR therapy (e.g., cetuximab) shows markedly improved response rates. Regulatory status varies by region; some combinations have received approvals/priority reviews.
- Other tumors (e.g., pancreatic, biliary, gynecologic): Early-phase data show activity but are not broadly approved.

Efficacy in NSCLC
- KRYSTAL-1 (phase 1/2, previously treated NSCLC):
  - Objective response rate (ORR) ~43%.
  - Median progression-free survival (PFS) ~6.5 months.
  - Median duration of response (DoR) ~12 months.
  - Intracranial activity: In a dedicated cohort with untreated brain metastases, intracranial ORR ~30–35% with meaningful intracranial disease control.
- KRYSTAL-12 (phase 3 vs docetaxel; reported 2024): Met its primary endpoint with superior PFS versus docetaxel in previously treated KRAS G12C NSCLC; ORR improved versus docetaxel. OS data immature at last report.

Efficacy in CRC
- Monotherapy ORR is low (~19% or less).
- Combination with cetuximab or panitumumab:
  - ORR ~30–46%, disease control rate high, with median PFS ~6–7 months in heavily pretreated cohorts.
  - These combinations address adaptive EGFR feedback signaling, a known resistance mechanism in CRC.

Safety and risk profile (adagrasib 600 mg BID)
- Common adverse events: Nausea, diarrhea, vomiting, decreased appetite, fatigue; most are grade 1–2 but grade ≥3 GI events can occur.
- Hepatotoxicity: Elevated AST/ALT reported; risk increased with recent/ongoing immunotherapy exposure. Monitor liver tests regularly; consider spacing from PD-1/PD-L1 therapy and cautious re-challenge.
- QTc prolongation: Known risk; obtain baseline and periodic ECGs, correct electrolytes, and avoid/add caution with other QT-prolonging drugs.
- Drug interactions: Adagrasib can inhibit CYP3A, CYP2C9, CYP2D6 and P-gp; be cautious with sensitive substrates (e.g., warfarin, certain DOACs, some antiarrhythmics, opioids, antidepressants). Review concomitant medications closely.
- Rare: ILD/pneumonitis; new/worsening respiratory symptoms warrant evaluation.

Potential benefits of transitioning to adagrasib (general)
- Targeted mechanism for KRAS p.G12C with meaningful response rates in NSCLC after chemo/IO and demonstrated intracranial activity.
- Oral therapy with manageable toxicity for most patients; quality-of-life benefits may be seen relative to cytotoxic chemotherapy.
- In CRC, using adagrasib with anti-EGFR therapy can confer clinically meaningful responses where options are limited.

Potential risks and considerations
- GI toxicity and hepatotoxicity may necessitate dose interruptions/reductions.
- QTc prolongation risk and significant drug–drug interactions may limit use or require careful management.
- Prior exposure to another KRAS G12C inhibitor (e.g., sotorasib) can confer cross-resistance; subsequent benefit from switching is often limited.
- Co-mutation context (e.g., KEAP1) may be associated with lower response or shorter benefit; brain metastases may still respond but require close monitoring.

How prognosis might change (general)
- NSCLC: Transitioning to adagrasib after standard therapies can improve disease control versus single-agent chemotherapy (e.g., docetaxel), with higher response rates and longer PFS on average. Individual prognosis depends on performance status, co-mutations, burden and sites of disease (especially CNS), and tolerance to therapy.
- CRC: In later lines, adagrasib plus anti-EGFR therapy can improve response and PFS versus best supportive care or single-agent options, potentially extending time to progression. Overall survival benefit is evolving and may be influenced by subsequent therapies.
- Brain metastases: The intracranial activity of adagrasib can favorably influence prognosis in patients with CNS involvement compared to agents with poor CNS penetration.

Key unknowns without patient specifics
- Tumor type and line of therapy (determines likelihood of benefit).
- Co-mutation profile (e.g., STK11/KEAP1) and PD-L1 (if NSCLC).
- Extent of CNS disease, hepatic function, and concomitant meds that may increase risk.
back to you: Orchestrator

Orchestrator: Micro-update: We’ve summarized general benefits, risks, and expected impact on prognosis with adagrasib for KRAS p.G12C. Next, I’ll ask a focused comparative evidence question so we can position adagrasib relative to sotorasib and account for co-mutations/resistance, then we’ll be ready to personalize guidance once we receive patient_4’s specifics.

MedicalResearch: Given the KRAS p.G12C mutation, what is the clinical evidence supporting use of KRAS inhibitors (e.g., adagrasib vs. sotorasib) in this context? Are there known resistance patterns or co-mutations (e.g., STK11, KEAP1) that affect efficacy? Please provide a concise, comparative summary suitable for clinical decision-making. After responding, yield back to the Orchestrator.

---

ASSISTANT (agent id: MedicalResearch):
I will use Microsoft GraphRAG to retrieve information with the following search terms: adagrasib KRAS G12C benefits risks NSCLC CRC Sources. Now querying Microsoft GraphRAG.
{"prompt":"adagrasib KRAS G12C benefits risks NSCLC CRC Sources"}
An error occurred while invoking the function graph_rag-process_prompt: Cannot serialize non-str key None
I have used Microsoft GraphRAG to retrieve the information. However, I encountered a technical issue invoking the Microsoft GraphRAG tool (error: “Cannot serialize non-str key None”) and could not retrieve any content or sources. Because the project guidelines require that I use Microsoft GraphRAG as the sole data source and present only its returned text and Sources, I cannot provide the requested evidence summary until I can successfully query the tool.

Next steps I can take:
- Retry the Microsoft GraphRAG query once the tool issue is resolved.
- If you can confirm that I should proceed after a tool reset, I will immediately re-run targeted searches with the following explicit search terms:
  - “adagrasib KRAS G12C NSCLC KRYSTAL-1 ORR PFS DoR intracranial activity safety Sources”
  - “adagrasib colorectal cancer KRAS G12C anti-EGFR cetuximab panitumumab efficacy safety Sources”
  - “KRYSTAL-12 adagrasib vs docetaxel PFS ORR Sources”
  - “adagrasib safety hepatotoxicity QTc prolongation drug interactions immunotherapy Sources”
- Alternatively, if you prefer, share any specific sub-questions (e.g., CNS activity, sequencing after sotorasib, co-mutation impact), and I will run focused GraphRAG queries for those once the tool is available.

Please let me know if you’d like me to attempt the queries again now or wait for confirmation that the GraphRAG tool is functioning.

---

ASSISTANT (agent id: Orchestrator):
Planned moderation steps:
- Confirm the objective and keep the plan aligned with your question.
- Identify missing patient-specific details needed for agent responses.
- Coordinate agent participation in sequence; ensure each agent yields back.
- Provide micro-updates after each agent’s input.
- Avoid making clinical recommendations myself; route evidence and guidance through agents.
- Validate outputs for completeness and move to next agent.

Micro-update: PatientHistory could not find a record for patient_4. MedicalResearch provided a general evidence overview for adagrasib in KRAS p.G12C disease; a deeper comparative query (adagrasib vs sotorasib) encountered a temporary search tool issue and will be retried later. Next, we need minimal clinical details from you so PatientStatus can proceed; then ClinicalGuidelines can address benefits/risks and likely impact on prognosis in your patient’s context.

Quick evidence highlights from MedicalResearch (general, not patient-specific):
- Potential benefits: In KRAS G12C–mutant NSCLC after prior therapy, adagrasib shows meaningful responses (ORR ~43%), median PFS ~6.5 months, and intracranial activity; oral administration may support quality of life. In CRC, activity improves notably when combined with an anti-EGFR agent (e.g., cetuximab).
- Key risks: GI AEs (nausea/diarrhea/vomiting), transaminase elevations (hepatotoxicity; caution near immunotherapy), QTc prolongation (ECGs/electrolytes and drug interaction review needed), and drug–drug interactions (CYP3A/2C9/2D6 and P-gp). Cross-resistance can limit benefit if a prior KRAS G12C inhibitor was used.

Plan and sequence (unchanged, pending your details):
1) PatientStatus → compile current structured status.
2) ClinicalGuidelines → explain benefits/risks of transitioning to adagrasib and how prognosis may change, based on PatientStatus.
3) ClinicalTrials → identify relevant KRAS G12C trials given the status.
4) MedicalResearch → finalize comparative nuances (adagrasib vs sotorasib; co-mutations) once the tool issue clears.
5) ReportCreation → optional tumor board document.
6) Radiology → optional if you share imaging.
Special rule: Each agent, after completing their task, must yield the chat back to me (the Orchestrator) by concluding with: “back to you: Orchestrator”.

User, to proceed, please provide the following for patient_4:
- Primary tumor and histology (e.g., NSCLC adenocarcinoma vs colorectal adenocarcinoma)
- Stage and sites of disease; presence/absence of brain metastases
- ECOG performance status
- Biomarkers: confirm KRAS p.G12C; co-mutations (e.g., STK11, KEAP1, TP53); PD-L1 (if NSCLC); MSI/MMR/TMB (if CRC/other)
- Prior therapies with dates and best response; note any prior KRAS G12C inhibitor exposure (e.g., sotorasib)
- Comorbidities and current medications (to assess QTc risk and drug interactions)
- Recent labs (AST/ALT, bilirubin, creatinine) and ECG QTc if available
- Optional: Any recent imaging (CT/MRI/X-ray) for Radiology review

Micro-update: Once you share these details, I will call PatientStatus to compile the patient’s current status, then move to ClinicalGuidelines for a patient-tailored discussion of adagrasib’s benefits/risks and its potential impact on prognosis. Would you like me to proceed in this order?

---

USER:
Orchestrator: Plan confirmed and aligned with the objective. Proceeding to Step 1.

PatientHistory: Please retrieve the full oncology timeline and key clinical data for patient_4. Specifically:
- Demographics: age, sex
- Primary tumor site and histology
- Stage at diagnosis and current stage; sites of disease; presence/absence of brain metastases
- Molecular biomarkers: confirm KRAS p.G12C and report co-mutations (e.g., STK11, KEAP1, TP53), PD-L1 (if NSCLC), MSI/MMR/TMB (if CRC/other), and any prior KRAS inhibitor exposure
- Prior systemic therapies, local therapies (surgery/radiation), lines of therapy with dates, regimens, best responses, and reasons for discontinuation
- Current performance status (ECOG), comorbidities, and current medications
- Recent labs (AST/ALT, bilirubin, creatinine) and ECG QTc if available
- Any notable adverse events from prior therapies
- Most recent imaging summary (CT/MRI/PET), including intracranial findings if applicable

If the record for patient_4 cannot be found, please explicitly state that, note what identifiers are missing or alternative lookup options, and provide guidance on the minimum data needed for downstream agents to proceed.

Please conclude with: “back to you: Orchestrator”.

---

ASSISTANT (agent id: PatientHistory):
Here is the complete patient data organized chronologically for clear understanding. This includes all relevant information for a tumor board review:
- 2021-03-27: Patient demographics and current status (for MTB overview)
    - 59-year-old female with metastatic non-small cell lung cancer (adenocarcinoma) of the left lung, stage T4N3M1a (IVA). Initial systemic therapy with weekly carboplatin/paclitaxel transitioned to q3-week carboplatin/paclitaxel plus pembrolizumab for 6 cycles (completed 2020-09-24), followed by maintenance pembrolizumab starting 2020-12-28. Molecular profiling (2020-08-10) showed KRAS p.G12C mutation; PD-L1 negative. Serial imaging in 2020 showed partial response; 2021 CT (02-15) showed slight increase in the lingular mass with improved hilar adenopathy; PET/CT on 2021-03-22 demonstrated progression with increased FDG-avid left lung mass and new/increased FDG-avid left hilar/infrahilar lymphadenopathy. As of 2021-03-27, plan is to discontinue pembrolizumab and initiate KRAS-directed therapy with adagrasib; patient referred for second opinion. Immune-related hypothyroidism managed with levothyroxine (TSH 159 on 2020-08-11 → treated; 2021-02-08 TSH 1.09; dose reduced to 75 mcg on 2021-03-01 after low TSH; 2021-03-20 thyroid labs WNL). Dysphagia due to Schatzki ring treated with EGD and balloon dilation on 2021-03-11, with symptomatic improvement. Coronary artery disease noted on imaging; cardiology consult completed 2021-03-12; PET/CT MPI with MFR scheduled for 2021-04-27.
    - Source: [Reason for visit: Follow-up for non-small cell lung cancer T4N3M1a (IVA). Completed treatment with carbo/taxol/keytruda x6 cycles on 2020-09-24. Currently on…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/0/source/0.html)
    - Source: [Reason for visit: Follow-up for non-small cell lung cancer T4N3M1a (IVA). Completed treatment with carbo/taxol/keytruda x6 cycles on 2020-09-24. Currently on…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/0/source/1.html)
- 2020-01-24: Follow-up CT chest identifies persistent lingular opacity and nodules
    - Follow-up CT chest (non-contrast) showed continued pulmonary opacity in the lingula suspicious for malignancy, slight enlargement of additional pulmonary nodules (including a new 2.5 mm right middle lobe nodule and an 8 mm left upper lobe nodule), and continued mediastinal and left hilar adenopathy. Pulmonology referral recommended.
    - Source: [Follow-up CT chest without contrast on 2020-01-24: Impression: 1. Continued presence of pulmonary opacity in the lingula, with no apparent air bronchograms.…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/1/source/0.html)
- 2020-03-07: Baseline PET/CT staging
    - PET/CT demonstrated a hypermetabolic lingular mass (3.4 x 3.8 cm), numerous hypermetabolic mediastinal nodes (including subcarinal 1.4 cm), an 8 mm hypermetabolic right lung base nodule, and a left supraclavicular node, consistent with stage IV disease.
    - Source: [2020-03-07: PET/CT hypermetabolic lingular mass approx 3.4 x 3.8 cm with numerous mediastinal nodes, 8 mm pulmonary nodule in the right lung base, and…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/2/source/0.html)
    - Source: [A PET scan on 2020-03-07 showed a left-sided supraclavicular lymph node (5 mm, SUV 3.6), a hypermetabolic lingular mass (3.4 x 3.8 cm, SUV 18.4), and a…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/2/source/1.html)
- 2020-03-30: Diagnostic bronchoscopy with EBUS-FNA confirms metastatic adenocarcinoma
    - EBUS-guided FNA of mediastinal nodes (stations 7 and 4R) and transbronchial FNA of the left lingula confirmed metastatic non-small cell carcinoma, favor adenocarcinoma; BAL from LLL also positive.
    - Source: [2020-03-30: Bronchoscopy with EBUS-guided FNA. Pathology diagnosis/interpretation: A. Lymph node, 7, EBUS guided fine needle aspiration -- metastatic non-small…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/3/source/0.html)
    - Source: [EBUS on 2020-03-30: Diagnosis/Interpretation: a. Lymph node, 7, EBUS guided fine needle aspiration -- metastatic non-small cell carcinoma, favor…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/3/source/1.html)
- 2020-04-22: Initial medical oncology evaluation and staging
    - Presented with chest heaviness/pain; earlier CT negative for PE but showed lingular consolidation, bilateral pulmonary nodules, mediastinal and left hilar adenopathy. Clinical impression: likely stage IV NSCLC; plan to start systemic chemotherapy (carboplatin/paclitaxel) with intent to transition to pembrolizumab; radiation to be considered based on response.
    - Source: [Jane M. Doe is a 59-year-old woman who presented in early December with increased chest heaviness and chest pain. A CT scan was performed to evaluate for…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/4/source/0.html)
- 2020-04-30: Chemotherapy education; planned weekly paclitaxel/carboplatin (weekly regimen)
    - Chemo education prior to first treatment. Planned weekly regimen: paclitaxel 135 mg IV and carboplatin 200 mg IV on day 1 of a 7‑day cycle (weekly), with potential dose adjustments as needed.
    - Source: [jane m doe is a 59 y.O. Female here for chemotherapy education prior to c1d1 of taxol + carboplatin. Chemotherapy protocol (reference): cycle 1 (treatment on…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/5/source/0.html)
- 2020-05-26: Transition plan to q3‑week carboplatin/paclitaxel (with continued agents)
    - One more weekly dose approved; will skip the following week for CT chest, then transition to chemotherapy once every 3 weeks starting on 2020-06-10 with the same medications.
    - Source: [Patient ok for 1 more weekly dose of chemotherapy. Will not do chemotherapy next week but will get ct scan of her chest. Will then plan on chemotherapy once…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/6/source/0.html)
- 2020-06-10: Cycle 1 Day 1 (q21-day) carboplatin/paclitaxel + pembrolizumab initiated
    - Initiated q3-week regimen including pembrolizumab 200 mg IV, paclitaxel 300 mg IV, and carboplatin 550 mg IV with standard premedications. Tolerated without complications.
    - Source: [2020-06-10 1006 CDT: Pembrolizumab (Keytruda) 200 mg in NaCl 0.9% 100 ml infusion, 200 mg, Intravenous, New bag 2020-06-10 1049 CDT: Paclitaxel (Taxol) 300 mg…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/7/source/0.html)
- 2020-08-04: Interim PET/CT shows partial response to treatment
    - Significant decrease in size and metabolic activity in mediastinal and left hilar nodes and in the primary lingular lesion (now 2.4 x 2.0 cm, SUV max 10.3 vs 17.6). No new hypermetabolic nodules; no suspicious abdominal/pelvic metastases.
    - Source: [Findings: within the chest there has been significant improvement and uptake of the lymph nodes in the mediastinum and left hilum. The lungs demonstrate…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/8/source/0.html)
- 2020-08-10: Molecular profiling (NGS): KRAS p.G12C; PD-L1 negative
    - NGS returned showing KRAS p.G12C mutation; PD-L1 negative. This informs eligibility for KRAS-directed therapy at progression.
    - Source: [- 2020-08-10 NGS returned showing KRAS p.G12C mutation. PD-L1 neg.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/9/source/0.html)
- 2020-08-11: Immune-related hypothyroidism detected; levothyroxine initiated
    - TSH markedly elevated at 159; levothyroxine started at 25 mcg daily. Plan to recheck TSH the next day and monitor weekly CBC/CMP.
    - Source: [Patients tsh resulted very high at 159. Dr. Miller would like her to start levothyroxine 25 mcg daily. We will recheck tsh tomorrow when patient has treatment.…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/10/source/0.html)
- 2020-09-24: Cycle 6 Day 1 carboplatin/paclitaxel + pembrolizumab (completion of induction)
    - Completed 6th q3-week cycle with pembrolizumab 200 mg IV, paclitaxel 300 mg IV, and carboplatin 550 mg IV. This completed 6 cycles of triplet therapy.
    - Source: [Cycle #6, Day 1 2020-09-24 1003 CDT: Pembrolizumab (Keytruda) 200 mg in NaCl 0.9% 100 ml infusion, 200 mg intravenous, new bag 2020-09-24 1039 CDT: Paclitaxel…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/11/source/0.html)
    - Source: [Completed treatment with carbo/taxol/keytruda x6 cycles on 2020-09-24.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/11/source/1.html)
- 2020-10-22: PET/CT demonstrates ongoing partial response
    - Lingular nodule decreased in SUV (6.9 from 10.3) and slight size reduction; several mediastinal/hilar nodes with decreased SUVs; overall impression of partial response to therapy; no extra-thoracic metastases.
    - Source: [2020-10-22: PET: Thorax: Twenty-seven by 22 millimeter lingular nodule now has a max SUV of 6.9; previously 29 by 24 millimeters with a max SUV of 10.3. -10…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/12/source/0.html)
- 2020-12-10: Consult: maintenance pembrolizumab recommended; no consolidative radiation
    - At outside consult, recommendation was to proceed with maintenance pembrolizumab and to avoid consolidative radiation; re-imaging every 3 months advised.
    - Source: [2020-12-10: Patient recently met with Dr. and was recommended maintenance pembrolizumab and he recommended against consolidative radiation. Recommended re-…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/13/source/0.html)
    - Source: [On 2020-12-10, the patient met with Dr. and was recommended maintenance pembrolizumab and advised against consolidative radiation.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/13/source/1.html)
- 2020-12-28: Maintenance pembrolizumab initiated (monotherapy)
    - Pembrolizumab 200 mg IV administered as Cycle 1, Day 1 of maintenance therapy; treatment completed without problems.
    - Source: [Medication Administration: - Pembrolizumab (Keytruda) 200 mg in NaCl 0.9% 100 ml infusion Dose: 200 mg Time: 2020-12-28 1406 CST Treatment Plan/Comments:…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/14/source/0.html)
- 2021-02-08: Labs stable on maintenance; pembrolizumab continued 2021-02-09
    - TSH 1.09 with stable labs; maintenance pembrolizumab continued on 2021-02-09.
    - Source: [2021-02-08: Patient's labs are stable. TSH: 1.09. Continued treatment with Keytruda on 2021-02-09.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/15/source/0.html)
- 2021-02-15: CT chest (non-contrast): slight increase in lingular mass; improved left hilar adenopathy
    - Lingular mass increased to 3.6 x 2.5 cm (from 2.7 x 2.4 cm). Left hilar adenopathy somewhat improved; no new adenopathy or new nodules; prior 5 mm RLL nodule resolved; LLL nodule now 10 x 4 mm. Coronary artery disease noted.
    - Source: [The lingular mass is now measured at 3.6 x 2.5 cm on image 92 of series 2. This was previously measured at 2.7 x 2.4 cm. Left hilar lymphadenopathy appears…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/16/source/0.html)
- 2021-03-01: Thyroid function low TSH; levothyroxine decreased to 75 mcg; new dysphagia symptoms
    - TSH low at 0.041 with normal free T4; levothyroxine dose decreased to 75 mcg. Patient reported dysphagia.
    - Source: [2021-03-01: TSH low at 0.041, free T4 WNL at 1.54. Decreased levothyroxine dose to 75 mcg. Patient c/o dysphagia.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/17/source/0.html)
- 2021-03-11: EGD with balloon dilation for Schatzki ring; biopsies benign
    - EGD revealed a tight stricture at the GE junction from chronic fibrosis consistent with Schatzki’s ring; balloon dilation performed up to 15 mm for 2 minutes without complications. Gastric antrum and duodenal biopsies showed normal mucosa and were negative (including for Helicobacter).
    - Source: [The z line appeared regular, but there was a tight stricture with narrowing at the ge junction from chronic fibrosis, consistent with shatzki's ring. Dilation…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/18/source/0.html)
    - Source: [Final diagnosis: a) duodenum, biopsy: 1. Normal duodenal mucosa 2. Negative for celiac disease and other enteropathy b) stomach, antrum, biopsy: 1. Normal…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/18/source/1.html)
- 2021-03-12: Cardiology evaluation; cardiac imaging scheduled
    - Cardiology consult completed. PET/CT myocardial perfusion imaging with MFR scheduled for 2021-04-27 to rule out significant CAD.
    - Source: [4. Coronary artery disease: Seen on CT. Consult placed to cardiology for further evaluation. Consult completed on 2021-03-12. Patient scheduled for a PET/CT…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/19/source/0.html)
- 2021-03-20: Oncology follow-up: disease appears slowly progressing; plan PET/CT and consider KRAS-directed therapy
    - At follow-up, disease appeared to be slowly progressing on recent imaging; PET/CT scheduled for 2021-03-22 prior to next Keytruda dose. Consideration for radiation and/or KRAS-directed therapy and second opinion discussed.
    - Source: [Patient due for treatment on 2021-03-21 with Keytruda, but rescheduled to 2021-03-22 after the PET scan. Disease appears to be slowly progressing. Will assess…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/20/source/0.html)
- 2021-03-22: PET/CT demonstrates disease progression; Keytruda administered same day
    - PET/CT showed increased intensely FDG-avid 4.1 cm left lung mass and new/increased intensely FDG-avid left hilar and infrahilar lymphadenopathy, consistent with progressive disease. Pembrolizumab was administered that day, prior to change in systemic therapy plan.
    - Source: [2021-03-22: Keytruda administered. PET/CT impression: 1. Increased intensely FDG avid 4.1 cm left lung mass, likely increased metabolically active…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/21/source/0.html)
- 2021-03-27: Therapy change planned due to progression: discontinue pembrolizumab; start adagrasib (KRAS-directed) and obtain second opinion
    - In light of progression on PET/CT, plan is to discontinue pembrolizumab and start adagrasib; referral to Dr. Ravih for second opinion.
    - Source: [Received Keytruda. As disease has progressed, will plan to discontinue pembrolizumab and start KRAS-directed treatment with adagrasib. Have patient follow up…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/22/source/0.html)
- 2021-03-27: Upcoming appointments arranged
    - Lab appointment on 2021-04-10 at 08:31, follow-up with Dr. Miller on 2021-04-11 at 11:01, with treatment after at 11:31 (same day, upstairs).
    - Source: [Lab appointment in - 2021-04-10 at 8:31am. Follow up with dr. Miller is scheduled for 2021-04-11 at 11:01am. -treatment will be right after at 11:31am upstairs.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/23/source/0.html)

back to you: Orchestrator

---

ASSISTANT (agent id: Orchestrator):
Planned moderation steps:
- Confirm objective and sequence; keep all contributions focused on your question.
- Use PatientHistory data to populate PatientStatus and identify any missing elements.
- Route to ClinicalGuidelines for a tailored discussion of benefits/risks and prognosis impact; avoid giving recommendations myself.
- Engage ClinicalTrials, MedicalResearch, Radiology, and ReportCreation to round out options, evidence, imaging context, and a consolidated report.
- Provide micro-updates after each agent response and ensure each agent yields back to me.
- Ask for any missing critical data from you to refine outputs.

Micro-update: PatientHistory has returned a detailed timeline for patient_4, confirming KRAS p.G12C NSCLC with progression after chemo-immunotherapy and a plan to start adagrasib. Next, I’ll have PatientStatus compile a structured current status for downstream agents.

PatientStatus, please compile the current structured status for patient_4 using the data below. Note unknowns explicitly and list any additional data you need to refine the status:
- Demographics: 59-year-old female
- Primary site/histology: Non-small cell lung cancer, adenocarcinoma, left lung
- Stage: IV (T4N3M1a, IVA) at diagnosis; current disease confined to thorax by imaging reports; no documented extrathoracic disease; brain metastases not documented
- Biomarkers: KRAS p.G12C positive (NGS 2020-08-10); PD-L1 negative; co-mutations (STK11/KEAP1/TP53) not reported; no prior KRAS inhibitor exposure
- Prior systemic therapy:
  - 2020-06-10 to 2020-09-24: Carboplatin + paclitaxel + pembrolizumab q3 weeks x6; best response: partial response
  - 2020-12-28 to 2021-03-22: Maintenance pembrolizumab; progression on PET/CT 2021-03-22
- Local therapy: No consolidative radiation; no surgery
- Current plan: Discontinue pembrolizumab; initiate adagrasib (as of 2021-03-27) and pursue second opinion
- Performance status: ECOG not documented
- Comorbidities: Coronary artery disease (under cardiology evaluation), immune-related hypothyroidism on levothyroxine; Schatzki ring s/p dilation
- Current medications: Levothyroxine 75 mcg daily; others not listed
- Recent labs/ECG: TSH normalized on therapy; AST/ALT/bilirubin/creatinine and QTc not provided
- Most recent imaging: PET/CT 2021-03-22 with increased FDG-avid 4.1 cm left lung mass and new/increased avid left hilar/infrahilar nodes; no reported extra-thoracic disease
Please conclude with: “back to you: Orchestrator”.

---

ASSISTANT (agent id: PatientStatus):
Planned actions:
- Review available PatientHistory data for completeness.
- Identify any missing required characteristics.
- Request the missing item(s) from PatientHistory.
- Once received, compile and present the structured current status.
- Validate that all required characteristics are included; if not, request follow-up data.

Required characteristics check:
- Age: available (59-year-old)
- Patient gender: available (female)
- Staging: available (Stage IV, T4N3M1a [IVA])
- Primary site: available (left lung)
- Histology: available (non-small cell lung cancer, adenocarcinoma)
- Biomarkers: available (KRAS p.G12C positive; PD-L1 negative; no additional co-mutations reported)
- Treatment history: available (carboplatin/paclitaxel + pembrolizumab induction with PR; maintenance pembrolizumab; progression on 2021-03-22; plan to start adagrasib)
- ECOG performance status: missing

I cannot present the full status until all required characteristics are available.

PatientHistory, can you provide me with the patient’s ECOG performance status at the most recent encounter (around 2021-03-22 to 2021-03-27)? If available, please also include any documented changes in ECOG over the prior two visits.

back to you: Orchestrator

---

ASSISTANT (agent id: Orchestrator):
Planned moderation steps:
- Confirm objective and keep sequence tight to answer your question.
- Fill the missing data PatientStatus needs to proceed.
- Move to ClinicalGuidelines for a tailored benefits/risks and prognosis discussion; I will not provide clinical recommendations myself.
- Provide micro-updates at each stage and ensure every agent yields back to me.
- Engage remaining agents (ClinicalTrials, MedicalResearch, Radiology, ReportCreation) to round out options, evidence, and a consolidated report.

Micro-update: PatientHistory has provided a detailed timeline confirming KRAS p.G12C NSCLC with progression after chemo-immunotherapy. PatientStatus needs ECOG to compile the formal status. I’ll request this from PatientHistory now so we can proceed to ClinicalGuidelines.

PatientHistory, please proceed with the following for patient_4:
- Extract and report ECOG performance status at the most recent encounter (2021-03-22 to 2021-03-27 timeframe). If not explicitly stated, return “not documented.”
- If available, include ECOG from the prior two visits as well.
- While reviewing, please also confirm:
  - Presence/absence of brain metastases or most recent CNS imaging status.
  - Most recent liver/kidney labs (AST, ALT, total bilirubin, creatinine) and any available ECG QTc.
  - Current medication list beyond levothyroxine (include any QT-prolonging agents or strong CYP3A/2C9/2D6 substrates/inhibitors if noted).
If any item is not found, state “not documented.”

Special rule reminder: After completing your task, yield the chat back to me by concluding with: “back to you: Orchestrator”.

---

ASSISTANT (agent id: PatientHistory):
Here is the complete patient data organized chronologically for clear understanding. This includes all relevant information for a tumor board review:
- 2021-03-27: Patient demographics and current status (for MTB overview)
    - 59-year-old female with metastatic non-small cell lung cancer (adenocarcinoma) of the left lung, stage T4N3M1a (IVA). Initial systemic therapy with weekly carboplatin/paclitaxel transitioned to q3-week carboplatin/paclitaxel plus pembrolizumab for 6 cycles (completed 2020-09-24), followed by maintenance pembrolizumab starting 2020-12-28. Molecular profiling (2020-08-10) showed KRAS p.G12C mutation; PD-L1 negative. Serial imaging in 2020 showed partial response; 2021 CT (02-15) showed slight increase in the lingular mass with improved hilar adenopathy; PET/CT on 2021-03-22 demonstrated progression with increased FDG-avid left lung mass and new/increased FDG-avid left hilar/infrahilar lymphadenopathy. As of 2021-03-27, plan is to discontinue pembrolizumab and initiate KRAS-directed therapy with adagrasib; patient referred for second opinion. Immune-related hypothyroidism managed with levothyroxine (TSH 159 on 2020-08-11 → treated; 2021-02-08 TSH 1.09; dose reduced to 75 mcg on 2021-03-01 after low TSH; 2021-03-20 thyroid labs WNL). Dysphagia due to Schatzki ring treated with EGD and balloon dilation on 2021-03-11, with symptomatic improvement. Coronary artery disease noted on imaging; cardiology consult completed 2021-03-12; PET/CT MPI with MFR scheduled for 2021-04-27.
    - Source: [Reason for visit: Follow-up for non-small cell lung cancer T4N3M1a (IVA). Completed treatment with carbo/taxol/keytruda x6 cycles on 2020-09-24. Currently on…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/0/source/0.html)
    - Source: [Reason for visit: Follow-up for non-small cell lung cancer T4N3M1a (IVA). Completed treatment with carbo/taxol/keytruda x6 cycles on 2020-09-24. Currently on…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/0/source/1.html)
- 2020-01-24: Follow-up CT chest identifies persistent lingular opacity and nodules
    - Follow-up CT chest (non-contrast) showed continued pulmonary opacity in the lingula suspicious for malignancy, slight enlargement of additional pulmonary nodules (including a new 2.5 mm right middle lobe nodule and an 8 mm left upper lobe nodule), and continued mediastinal and left hilar adenopathy. Pulmonology referral recommended.
    - Source: [Follow-up CT chest without contrast on 2020-01-24: Impression: 1. Continued presence of pulmonary opacity in the lingula, with no apparent air bronchograms.…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/1/source/0.html)
- 2020-03-07: Baseline PET/CT staging
    - PET/CT demonstrated a hypermetabolic lingular mass (3.4 x 3.8 cm), numerous hypermetabolic mediastinal nodes (including subcarinal 1.4 cm), an 8 mm hypermetabolic right lung base nodule, and a left supraclavicular node, consistent with stage IV disease.
    - Source: [2020-03-07: PET/CT hypermetabolic lingular mass approx 3.4 x 3.8 cm with numerous mediastinal nodes, 8 mm pulmonary nodule in the right lung base, and…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/2/source/0.html)
    - Source: [A PET scan on 2020-03-07 showed a left-sided supraclavicular lymph node (5 mm, SUV 3.6), a hypermetabolic lingular mass (3.4 x 3.8 cm, SUV 18.4), and a…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/2/source/1.html)
- 2020-03-30: Diagnostic bronchoscopy with EBUS-FNA confirms metastatic adenocarcinoma
    - EBUS-guided FNA of mediastinal nodes (stations 7 and 4R) and transbronchial FNA of the left lingula confirmed metastatic non-small cell carcinoma, favor adenocarcinoma; BAL from LLL also positive.
    - Source: [2020-03-30: Bronchoscopy with EBUS-guided FNA. Pathology diagnosis/interpretation: A. Lymph node, 7, EBUS guided fine needle aspiration -- metastatic non-small…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/3/source/0.html)
    - Source: [EBUS on 2020-03-30: Diagnosis/Interpretation: a. Lymph node, 7, EBUS guided fine needle aspiration -- metastatic non-small cell carcinoma, favor…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/3/source/1.html)
- 2020-04-22: Initial medical oncology evaluation and staging
    - Presented with chest heaviness/pain; earlier CT negative for PE but showed lingular consolidation, bilateral pulmonary nodules, mediastinal and left hilar adenopathy. Clinical impression: likely stage IV NSCLC; plan to start systemic chemotherapy (carboplatin/paclitaxel) with intent to transition to pembrolizumab; radiation to be considered based on response.
    - Source: [Jane M. Doe is a 59-year-old woman who presented in early December with increased chest heaviness and chest pain. A CT scan was performed to evaluate for…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/4/source/0.html)
- 2020-04-30: Chemotherapy education; planned weekly paclitaxel/carboplatin (weekly regimen)
    - Chemo education prior to first treatment. Planned weekly regimen: paclitaxel 135 mg IV and carboplatin 200 mg IV on day 1 of a 7‑day cycle (weekly), with potential dose adjustments as needed.
    - Source: [jane m doe is a 59 y.O. Female here for chemotherapy education prior to c1d1 of taxol + carboplatin. Chemotherapy protocol (reference): cycle 1 (treatment on…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/5/source/0.html)
- 2020-05-26: Transition plan to q3‑week carboplatin/paclitaxel (with continued agents)
    - One more weekly dose approved; will skip the following week for CT chest, then transition to chemotherapy once every 3 weeks starting on 2020-06-10 with the same medications.
    - Source: [Patient ok for 1 more weekly dose of chemotherapy. Will not do chemotherapy next week but will get ct scan of her chest. Will then plan on chemotherapy once…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/6/source/0.html)
- 2020-06-10: Cycle 1 Day 1 (q21-day) carboplatin/paclitaxel + pembrolizumab initiated
    - Initiated q3-week regimen including pembrolizumab 200 mg IV, paclitaxel 300 mg IV, and carboplatin 550 mg IV with standard premedications. Tolerated without complications.
    - Source: [2020-06-10 1006 CDT: Pembrolizumab (Keytruda) 200 mg in NaCl 0.9% 100 ml infusion, 200 mg, Intravenous, New bag 2020-06-10 1049 CDT: Paclitaxel (Taxol) 300 mg…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/7/source/0.html)
- 2020-08-04: Interim PET/CT shows partial response to treatment
    - Significant decrease in size and metabolic activity in mediastinal and left hilar nodes and in the primary lingular lesion (now 2.4 x 2.0 cm, SUV max 10.3 vs 17.6). No new hypermetabolic nodules; no suspicious abdominal/pelvic metastases.
    - Source: [Findings: within the chest there has been significant improvement and uptake of the lymph nodes in the mediastinum and left hilum. The lungs demonstrate…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/8/source/0.html)
- 2020-08-10: Molecular profiling (NGS): KRAS p.G12C; PD-L1 negative
    - NGS returned showing KRAS p.G12C mutation; PD-L1 negative. This informs eligibility for KRAS-directed therapy at progression.
    - Source: [- 2020-08-10 NGS returned showing KRAS p.G12C mutation. PD-L1 neg.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/9/source/0.html)
- 2020-08-11: Immune-related hypothyroidism detected; levothyroxine initiated
    - TSH markedly elevated at 159; levothyroxine started at 25 mcg daily. Plan to recheck TSH the next day and monitor weekly CBC/CMP.
    - Source: [Patients tsh resulted very high at 159. Dr. Miller would like her to start levothyroxine 25 mcg daily. We will recheck tsh tomorrow when patient has treatment.…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/10/source/0.html)
- 2020-09-24: Cycle 6 Day 1 carboplatin/paclitaxel + pembrolizumab (completion of induction)
    - Completed 6th q3-week cycle with pembrolizumab 200 mg IV, paclitaxel 300 mg IV, and carboplatin 550 mg IV. This completed 6 cycles of triplet therapy.
    - Source: [Cycle #6, Day 1 2020-09-24 1003 CDT: Pembrolizumab (Keytruda) 200 mg in NaCl 0.9% 100 ml infusion, 200 mg intravenous, new bag 2020-09-24 1039 CDT: Paclitaxel…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/11/source/0.html)
    - Source: [Completed treatment with carbo/taxol/keytruda x6 cycles on 2020-09-24.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/11/source/1.html)
- 2020-10-22: PET/CT demonstrates ongoing partial response
    - Lingular nodule decreased in SUV (6.9 from 10.3) and slight size reduction; several mediastinal/hilar nodes with decreased SUVs; overall impression of partial response to therapy; no extra-thoracic metastases.
    - Source: [2020-10-22: PET: Thorax: Twenty-seven by 22 millimeter lingular nodule now has a max SUV of 6.9; previously 29 by 24 millimeters with a max SUV of 10.3. -10…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/12/source/0.html)
- 2020-12-10: Consult: maintenance pembrolizumab recommended; no consolidative radiation
    - At outside consult, recommendation was to proceed with maintenance pembrolizumab and to avoid consolidative radiation; re-imaging every 3 months advised.
    - Source: [2020-12-10: Patient recently met with Dr. and was recommended maintenance pembrolizumab and he recommended against consolidative radiation. Recommended re-…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/13/source/0.html)
    - Source: [On 2020-12-10, the patient met with Dr. and was recommended maintenance pembrolizumab and advised against consolidative radiation.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/13/source/1.html)
- 2020-12-28: Maintenance pembrolizumab initiated (monotherapy)
    - Pembrolizumab 200 mg IV administered as Cycle 1, Day 1 of maintenance therapy; treatment completed without problems.
    - Source: [Medication Administration: - Pembrolizumab (Keytruda) 200 mg in NaCl 0.9% 100 ml infusion Dose: 200 mg Time: 2020-12-28 1406 CST Treatment Plan/Comments:…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/14/source/0.html)
- 2021-02-08: Labs stable on maintenance; pembrolizumab continued 2021-02-09
    - TSH 1.09 with stable labs; maintenance pembrolizumab continued on 2021-02-09.
    - Source: [2021-02-08: Patient's labs are stable. TSH: 1.09. Continued treatment with Keytruda on 2021-02-09.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/15/source/0.html)
- 2021-02-15: CT chest (non-contrast): slight increase in lingular mass; improved left hilar adenopathy
    - Lingular mass increased to 3.6 x 2.5 cm (from 2.7 x 2.4 cm). Left hilar adenopathy somewhat improved; no new adenopathy or new nodules; prior 5 mm RLL nodule resolved; LLL nodule now 10 x 4 mm. Coronary artery disease noted.
    - Source: [The lingular mass is now measured at 3.6 x 2.5 cm on image 92 of series 2. This was previously measured at 2.7 x 2.4 cm. Left hilar lymphadenopathy appears…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/16/source/0.html)
- 2021-03-01: Thyroid function low TSH; levothyroxine decreased to 75 mcg; new dysphagia symptoms
    - TSH low at 0.041 with normal free T4; levothyroxine dose decreased to 75 mcg. Patient reported dysphagia.
    - Source: [2021-03-01: TSH low at 0.041, free T4 WNL at 1.54. Decreased levothyroxine dose to 75 mcg. Patient c/o dysphagia.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/17/source/0.html)
- 2021-03-11: EGD with balloon dilation for Schatzki ring; biopsies benign
    - EGD revealed a tight stricture at the GE junction from chronic fibrosis consistent with Schatzki’s ring; balloon dilation performed up to 15 mm for 2 minutes without complications. Gastric antrum and duodenal biopsies showed normal mucosa and were negative (including for Helicobacter).
    - Source: [The z line appeared regular, but there was a tight stricture with narrowing at the ge junction from chronic fibrosis, consistent with shatzki's ring. Dilation…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/18/source/0.html)
    - Source: [Final diagnosis: a) duodenum, biopsy: 1. Normal duodenal mucosa 2. Negative for celiac disease and other enteropathy b) stomach, antrum, biopsy: 1. Normal…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/18/source/1.html)
- 2021-03-12: Cardiology evaluation; cardiac imaging scheduled
    - Cardiology consult completed. PET/CT myocardial perfusion imaging with MFR scheduled for 2021-04-27 to rule out significant CAD.
    - Source: [4. Coronary artery disease: Seen on CT. Consult placed to cardiology for further evaluation. Consult completed on 2021-03-12. Patient scheduled for a PET/CT…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/19/source/0.html)
- 2021-03-20: Oncology follow-up: disease appears slowly progressing; plan PET/CT and consider KRAS-directed therapy
    - At follow-up, disease appeared to be slowly progressing on recent imaging; PET/CT scheduled for 2021-03-22 prior to next Keytruda dose. Consideration for radiation and/or KRAS-directed therapy and second opinion discussed.
    - Source: [Patient due for treatment on 2021-03-21 with Keytruda, but rescheduled to 2021-03-22 after the PET scan. Disease appears to be slowly progressing. Will assess…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/20/source/0.html)
- 2021-03-22: PET/CT demonstrates disease progression; Keytruda administered same day
    - PET/CT showed increased intensely FDG-avid 4.1 cm left lung mass and new/increased intensely FDG-avid left hilar and infrahilar lymphadenopathy, consistent with progressive disease. Pembrolizumab was administered that day, prior to change in systemic therapy plan.
    - Source: [2021-03-22: Keytruda administered. PET/CT impression: 1. Increased intensely FDG avid 4.1 cm left lung mass, likely increased metabolically active…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/21/source/0.html)
- 2021-03-27: Therapy change planned due to progression: discontinue pembrolizumab; start adagrasib (KRAS-directed) and obtain second opinion
    - In light of progression on PET/CT, plan is to discontinue pembrolizumab and start adagrasib; referral to Dr. Ravih for second opinion.
    - Source: [Received Keytruda. As disease has progressed, will plan to discontinue pembrolizumab and start KRAS-directed treatment with adagrasib. Have patient follow up…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/22/source/0.html)
- 2021-03-27: Upcoming appointments arranged
    - Lab appointment on 2021-04-10 at 08:31, follow-up with Dr. Miller on 2021-04-11 at 11:01, with treatment after at 11:31 (same day, upstairs).
    - Source: [Lab appointment in - 2021-04-10 at 8:31am. Follow up with dr. Miller is scheduled for 2021-04-11 at 11:01am. -treatment will be right after at 11:31am upstairs.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_timeline/entry/23/source/0.html)
- 2021-03-27 to prior visits: ECOG, CNS, labs, and current meds summary for treatment planning
    - ECOG performance status:
        - 2021-03-27: not documented.
        - 2021-03-20: ECOG 1.
        - 2020-04-30: ECOG 1.
        - Sources: [Heme|Onc progress note date of service: 2021-03-27 We reviewed her CT scans and brain MRI done here together and compared them with multiple prior scans.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_data_answer/551b3b4d-5651-4e8e-9148-3b798bce0a13/source/0.html) | [ECOG scale (0-4): 1 - ALT (SGPT) 16 IU/L - AST (SGOT) 30 IU/L - Bilirubin, total 0.4 mg/dL - Creatinine 0.84 mg/dL - Cyclobenzaprine (Flexeril) 10 mg tablet,…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_data_answer/551b3b4d-5651-4e8e-9148-3b798bce0a13/source/1.html) | [Chemotherapy education visit date of visit: 2020-04-30 Ecog performance status:1](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_data_answer/551b3b4d-5651-4e8e-9148-3b798bce0a13/source/2.html)
    - CNS status:
        - Brain metastases: not documented/absent in chart; no abnormal CNS findings referenced.
        - Most recent CNS imaging: brain MRI referenced without abnormalities; date/impression not documented.
        - Source: [Heme|Onc progress note date of service: 2021-03-27 We reviewed her CT scans and brain MRI done here together and compared them with multiple prior scans.](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_data_answer/551b3b4d-5651-4e8e-9148-3b798bce0a13/source/0.html)
    - Recent labs (most recent values and date: 2021-03-20):
        - AST 30 IU/L; ALT 16 IU/L; total bilirubin 0.4 mg/dL; creatinine 0.84 mg/dL.
        - Source: [ECOG scale (0-4): 1 - ALT (SGPT) 16 IU/L - AST (SGOT) 30 IU/L - Bilirubin, total 0.4 mg/dL - Creatinine 0.84 mg/dL - Cyclobenzaprine (Flexeril) 10 mg tablet,…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_data_answer/551b3b4d-5651-4e8e-9148-3b798bce0a13/source/1.html)
    - ECG:
        - QTc: not documented.
    - Current medications beyond levothyroxine (with QT/CYP notes):
        - Cyclobenzaprine 10 mg tablet TID PRN (QT prolongation risk; CYP1A2/3A4/2D6 substrate).
        - Ibuprofen 800 mg q8h PRN (CYP2C9 substrate; not QT-prolonging).
        - Oxycodone 2.5–5 mg q6h PRN (CYP3A4 and CYP2D6 substrate; not QT-prolonging).
        - Pregabalin 150 mg HS (not CYP; not QT-prolonging).
        - Rosuvastatin 20 mg daily (minimal CYP; not QT-prolonging).
        - Trazodone 100 mg HS PRN (QT prolongation risk; CYP3A4 substrate).
        - No strong CYP3A/CYP2C9/CYP2D6 inhibitors/inducers documented.
        - Source: [ECOG scale (0-4): 1 - ALT (SGPT) 16 IU/L - AST (SGOT) 30 IU/L - Bilirubin, total 0.4 mg/dL - Creatinine 0.84 mg/dL - Cyclobenzaprine (Flexeril) 10 mg tablet,…](https://app-hao-lmat-evx.azurewebsites.net/view/a6579bfa0acc3910cbb8a256d0a4a890cbd851c667b599271f8c87cd453a9f0c/patient_4/patient_data_answer/551b3b4d-5651-4e8e-9148-3b798bce0a13/source/1.html)

back to you: Orchestrator

---

ASSISTANT (agent id: Orchestrator):
Planned moderation steps:
- Keep the workflow aligned with your question about benefits/risks and prognosis with adagrasib.
- Use the retrieved chart data to compile a complete, structured PatientStatus.
- Route to ClinicalGuidelines for a tailored benefits/risks and prognosis discussion; I will not provide recommendations myself.
- Engage ClinicalTrials to surface relevant KRAS G12C trials; invite Radiology and ReportCreation as appropriate.
- Provide micro-updates after each agent response and ensure each agent yields back to me.

Micro-update: PatientHistory has now provided ECOG (most recently documented as 1 on 2021-03-20), CNS status (no brain metastases documented; brain MRI referenced without abnormalities), recent LFT/renal labs within normal limits (3/20/21), QTc not documented, and a current med list that includes cyclobenzaprine and trazodone (QT-prolonging) plus several CYP substrates. Next, I’ll have PatientStatus compile the structured status so ClinicalGuidelines can address adagrasib’s benefits/risks and potential impact on prognosis in this patient.

PatientStatus, please compile the structured current status for patient_4. Use the following, noting any uncertainties explicitly:
- Demographics: 59-year-old female
- Primary site/histology: Non-small cell lung cancer, adenocarcinoma, left lung
- Stage: IV (T4N3M1a, IVA) at diagnosis; current progression confined to thorax (left lung mass; left hilar/infrahilar nodes); no documented extrathoracic disease
- CNS: Brain metastases not documented; brain MRI referenced without abnormalities; no dedicated report available
- Biomarkers: KRAS p.G12C positive (NGS 2020-08-10); PD-L1 negative; co-mutations (STK11/KEAP1/TP53) not reported; no prior KRAS inhibitor exposure
- Prior systemic therapy:
  - 2020-06-10 → 2020-09-24: Carboplatin + paclitaxel + pembrolizumab q3w x6; best response: partial response
  - 2020-12-28 → 2021-03-22: Maintenance pembrolizumab; progressive disease on PET/CT 2021-03-22
- Local therapy: No consolidative radiation; no surgery
- Current plan: Discontinue pembrolizumab; initiate adagrasib (KRAS-directed therapy) per 2021-03-27 note; second opinion referral placed
- ECOG performance status: Most recently documented ECOG 1 (2021-03-20); ECOG not documented on 2021-03-27
- Comorbidities: Coronary artery disease (under evaluation), immune-related hypothyroidism (on levothyroxine), Schatzki ring s/p dilation
- Current medications of note (beyond levothyroxine 75 mcg daily):
  - Cyclobenzaprine 10 mg TID PRN (QT-prolongation risk; CYP1A2/3A4/2D6 substrate)
  - Trazodone 100 mg HS PRN (QT-prolongation risk; CYP3A4 substrate)
  - Oxycodone 2.5–5 mg q6h PRN (CYP3A4/2D6 substrate)
  - Ibuprofen 800 mg q8h PRN (CYP2C9 substrate); Pregabalin 150 mg HS; Rosuvastatin 20 mg daily
  - No strong CYP3A/CYP2C9/CYP2D6 inhibitors or inducers documented
- Most recent labs (2021-03-20): AST 30 IU/L; ALT 16 IU/L; total bilirubin 0.4 mg/dL; creatinine 0.84 mg/dL
- ECG: QTc not documented
Please present:
- A concise, structured status summary
- Any additional data needs or monitoring considerations relevant to targeted therapy with adagrasib (e.g., QTc baseline)
Each agent, after completing their task, must yield the chat back to me (the Orchestrator). Conclude with: “back to you: Orchestrator”.

Next steps after PatientStatus:
- ClinicalGuidelines → explain potential benefits and risks of transitioning to adagrasib now and how prognosis may change, based on the compiled status.
- ClinicalTrials → list active/relevant KRAS G12C trials for which this patient might qualify.
- Radiology → optional; if needed, comment on imaging context; if no images are available for review, please state that.
- ReportCreation → optional; produce a tumor board-ready document summarizing the above. Would you like me to invoke ReportCreation after ClinicalGuidelines and ClinicalTrials?

---

